Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance

Executive Summary

Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
Advertisement

Related Content

Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus
User Fee Program Renewal Gets Trickier After Ruling In Omnitrope Court Case
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
Tale Of Two Pathways: Follow-On Biologics Move Forth In EU, Stall In U.S.
Follow-Ons Off? FDA Shelves Near-Term Plans For Biologics Documents
Ista Tries To Void Vitrase NME Status: Will Less Exclusivity Mean More?
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No
Generic Biologics: 505(b)(2) Route Still Open, But Scientific Issues Unresolved

Topics

Advertisement
UsernamePublicRestriction

Register

PS046334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel